CADTH publishes final recommendation for Mayzent

CADTH

23 July 2020 - The recommendation relates to the use of siponomid for the treatment of patients with secondary progressive multiple sclerosis.

The CADTH Canadian Drug Expert Committee has recommended that siponimod be reimbursed for the treatment of patients with secondary progressive multiple sclerosis with active disease evidenced by relapses or imaging features characteristic of multiple sclerosis inflammatory activity, to delay the progression of physical disability, only if certain conditions are met.

This includes a reduction in price; siponimod was associated with incremental QALYs of 0.75 and incremental health care costs of $146,424, leading to an incremental cost effectiveness ratio of $194,007/QALY gained when compared with best supportive care.

Read CADTH Final Recommendation for Mayzent

Michael Wonder

Posted by:

Michael Wonder